Drugs / NZV930
last change Sep 2023 re-read 2 minutes ago

NZV930

also known as SRF-373
Developed for
cancer
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT04237649 Feb 2020 → Sep 2023 cancer Novartis Pharmaceuticals Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NZV930 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04237649
Known as SRF-373 ChEMBL registry synonym — accepted as the source's own label CHEMBL4594582